Arcellx, Inc.(ACLX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,957 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ACLX Stock Analysis & AI Quality Score
Data updated 2026-08-29AI stock analysis and institutional research for Arcellx, Inc. (ACLX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ACLX at 3.6/100 on a 32-signal composite quality model, placing it at rank #2,957 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (0.3) and institutional flow (1.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2025), Arcellx, Inc. reports quarterly revenue of $1.7M, net income of $-58.1M, free cash flow of $-58.9M. Top institutional holders of ACLX by reported 13-F value include GILEAD SCIENCES, Paradigm Biocapital Advisors, BlackRock, based on the most recent SEC filings. ACLX trades on the Nasdaq exchange and files with the SEC under CIK 1786205. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ACLX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Arcellx, Inc. directly from SEC EDGAR. Arcellx, Inc.'s 13F Pro composite quality score has ranged between 4 and 34 since 2024, currently 3.6 — a declining long-term trajectory across 55 quarterly and live scoring snapshots.
Revenue
Q4 2025
$1.7M
Net Income
Q4 2025
$-58.1M
Free Cash Flow
Q4 2025
$-58.9M
ROIC
Q4 2025
-63.3%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-79.4% YoYNet Income
-113.3% YoYOperating Income
-84.0% YoYEPS (Diluted)
-103.5% YoYTotal Assets
-15.1% YoYOp. Cash Flow
-151.9% YoYFree Cash Flow
-119.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $22.3M -79.4% | $107.9M -2.2% | $110.3M | — | — | — |
| Net Income | $-228.9M -113.3% | $-107.3M -51.9% | $-70.7M +62.5% | $-188.7M -190.4% | $-65.0M | — |
| Operating Income | $-253.1M -84.0% | $-137.6M -53.1% | $-89.9M +53.0% | $-191.3M -194.2% | $-65.0M | — |
| EPS (Diluted) | $-4.07 -103.5% | $-2.00 -36.1% | $-1.47 +71.7% | $-5.19 +96.4% | $-145.55 | — |
| Total Assets | $604.0M -15.1% | $711.3M -13.8% | $825.1M +162.9% | $313.8M +143.7% | $128.8M | — |
| Operating Cash Flow | $-210.3M -151.9% | $-83.5M -140.2% | $207.6M +309.0% | $-99.3M -83.1% | $-54.2M | — |
| Free Cash Flow | $-212.6M -119.4% | $-96.9M -152.1% | $186.1M +283.2% | $-101.6M -69.2% | $-60.0M | — |
Get alerted when ACLX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Arcellx, Inc. including:
Top Institutional Holders of ACLX
GILEAD SCIENCES, INC.
$771.7M6,720,803 shParadigm Biocapital Advisors LP
$663.0M5,774,016 shBlackRock, Inc.
$453.0M3,945,238 shNEA Management Company, LLC
$349.7M3,045,262 shPentwater Capital Management LP
$329.5M2,870,000 shVANGUARD CAPITAL MANAGEMENT LLC
$278.5M2,425,218 shVANGUARD PORTFOLIO MANAGEMENT LLC
$278.4M2,424,818 shSR ONE CAPITAL MANAGEMENT, LP
$269.4M2,346,630 shFIL Ltd
$268.6M2,339,192 shHBK INVESTMENTS L P
$261.6M2,278,517 sh
| Fund | Value | Shares |
|---|---|---|
| GILEAD SCIENCES, INC. | $771.7M | 6,720,803 |
| Paradigm Biocapital Advisors LP | $663.0M | 5,774,016 |
| BlackRock, Inc. | $453.0M | 3,945,238 |
| NEA Management Company, LLC | $349.7M | 3,045,262 |
| Pentwater Capital Management LP | $329.5M | 2,870,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $278.5M | 2,425,218 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $278.4M | 2,424,818 |
| SR ONE CAPITAL MANAGEMENT, LP | $269.4M | 2,346,630 |
| FIL Ltd | $268.6M | 2,339,192 |
| HBK INVESTMENTS L P | $261.6M | 2,278,517 |
Companies Similar to ACLX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
AMICUS THERAPEUTICS, INC.
Apellis Pharmaceuticals, Inc.
CRESCENT BIOPHARMA, INC.
FATE THERAPEUTICS INC
Gossamer Bio, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ACLX on your watchlist
Track score changes the day Arcellx, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ACLX a good stock to buy?
13F Pro's AI-powered analysis of Arcellx, Inc. (ACLX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ACLX are available on the ACLX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ACLX is classified as a mid company.
Which hedge funds own ACLX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ACLX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Arcellx, Inc.'s investment landscape.